Cytokinetics’ (CYTK) investigational product omecamtiv mecarbil, the firm’s potential treatment for heart failure with reduced ejection fraction, …

From the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) Prostate Cancer A presentation …

RegenxBio (RGNX), a clinical-stage gene therapy firm with a proprietary NAV® Technology Platform, will host an analyst and investor …

Portola Pharmaceuticals (PTLA) announced full results from ANNEXA-4, Phase 3b/4 trial of its Factor Xa inhibitor antidote Andexxa®  in …

Prohost Letter #428 End of the Year Decisions ~ Part 3 In Part 3 of this …

Halozyme Therapeutics (HALO) and argenx (ARGX) announced a global collaboration and license agreement offering argenx the right to use …

Merck (MRK) announced its Q4 2018 financial results. The firm outperformed itself and delighted us with regard …

Can a liquid biopsy test be accurate enough for physicians to rely on in differentiating between …

Prohost Letter #427 End of the Year Decisions ~ Part 2 As a result of the unexpected …

Lipocine (LPCN), a specialty pharmaceutical company, announced that an approximately eight-week top-line study using LPCN 1144 …